Synonym
Phenacemide; HSDB3380; HSDB-3380; HSDB 3380
IUPAC/Chemical Name
N-carbamoyl-2-phenylacetamide
InChi Key
XPFRXWCVYUEORT-UHFFFAOYSA-N
InChi Code
InChI=1S/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)
SMILES Code
NC(NC(Cc1ccccc1)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
178.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Cahen R, Martin A, Francois B, Baltassat P, Louisot P. Creatinine metabolism impairment by an anticonvulsant drug, phenacemide. Ann Pharmacother. 1994 Jan;28(1):49-51. doi: 10.1177/106002809402800110. PMID: 8123960.
2: AIRD RB, GORDON NS, GREGG HC. Use of phenacemide (phenurone) in treatment of narcolepsy and cataplexy; a preliminary report. AMA Arch Neurol Psychiatry. 1953 Oct;70(4):510-5. doi: 10.1001/archneurpsyc.1953.02320340100010. PMID: 13091500.
3: Coker SB, Holmes EW, Egel RT. Phenacemide therapy of complex partial epilepsy in children: determination of plasma drug concentrations. Neurology. 1987 Dec;37(12):1861-6. doi: 10.1212/wnl.37.12.1861. PMID: 3683877.
4: TYLER MW, KING EQ. Phenacemide in treatment of epilepsy. J Am Med Assoc. 1951 Sep 1;147(1):17-21. doi: 10.1001/jama.1951.03670180023004. PMID: 14861009.
5: Richards RK, Bjornsson TD, Waterbury LD. Rise in serum and urine creatinine after phenacemide. Clin Pharmacol Ther. 1978 Apr;23(4):430-7. doi: 10.1002/cpt1978234430. PMID: 630790.
6: Ono N, Furukawa T. [Central effects of clonazepam]. Nihon Yakurigaku Zasshi. 1976 Apr;72(3):297-312. Japanese. doi: 10.1254/fpj.72.297. PMID: 986989.
7: Camerman A, Camerman N. Ethylphenacemide and phenacemide: conformational similarities to diphenylhydantoin and stereochemical basis of anticonvulsant activity. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1264-6. doi: 10.1073/pnas.74.3.1264. PMID: 265568; PMCID: PMC430664.
8: Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? J Intern Med. 1999 Sep;246(3):247-52. doi: 10.1046/j.1365-2796.1999.00515.x. PMID: 10475992.
9: Connolly P, Sirmans S, Belmonte AA, Darling CM. GLC determination of phenacemide in tablets. J Pharm Sci. 1982 Nov;71(11):1287-8. doi: 10.1002/jps.2600711126. PMID: 7175726.
10: Richards RK. Structure-activity relationships in the effects of phenacemide analogs on serum creatinine and anticonvulsant activity. Arch Int Pharmacodyn Ther. 1980 Mar;244(1):107-12. PMID: 7416882.
